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Summary The cytochromes P450 have a central role in the oxidative activation and detoxification of a wide range of xenobiotics, including
many carcinogens and several anti-cancer drugs. Thus the cytochrome P450 enzyme system has important roles in both tumour
development and influencing the response of tumours to chemotherapy. Stomach cancer is one of the commonest tumours of the alimentary
tract and environmental factors, including dietary factors, have been implicated in the development of this tumour. This type of tumour has a
poor prognosis and responds poorly to current therapies. In this study, the presence and cellular localization of several major forms of P450,
CYPlA, CYP2E1 and CYP3A have been investigated in stomach cancer and compared with their expression in normal stomach. There was
enhanced expression of CYP1A and CYP3A in stomach cancerwith CYP1A present in 51% and CYP3A present in 28% of cases. In contrast,
no P450 was identified in normal stomach. The presence of CYPlA and CYP3A in stomach cancer provides further evidence for the
enhanced expression of specific forms of cytochrome P450 in tumours and may be important therapeutically for the development of anti-
cancer drugs that are activated by these forms of P450.
Keywords: cytochrome P450; neoplasm; stomach
Stomach cancer is one ofthe commonest cancers ofthe alimentary
tract and has a relatively poor prognosis with limited response to
current modes of therapy (Thompson et al, 1993). Environmental
factors, particularly dietary factors, are considered to be important
in the aetiology and pathogenesis of this type of tumour. The
current model for development of stomach cancer proposes that
this type of tumour develops from normal stomach through
different types ofintestinal metaplasia (Correa, 1988).
The cytochromes P450 (P450) are a multi-gene family (Nelson
et al, 1996) of constitutive and inducible haem-containing
enzymes with acritical role in the metabolism ofadiverse range of
xenobiotics, including many potential carcinogens (Shimada and
Guengerich, 1991; Gonzalez and Gelboin, 1994; Roberts-
Thomson et al, 1995) and various anti-cancer drugs (Kivisto et al,
1995a). Thus, the P450s are considered to have a central role in
chemical carcinogenesis and are involved in tumour initiation and
promotion as they can activate or deactivate most carcinogens
(Gonzalez and Gelboin, 1994). Furthermore the P450s can influ-
ence the response of established tumours to anti-cancer drugs by
metabolizing these drugs both in normal tissues and in tumour
cells. In addition, P450s may have a role in cell regulation, in view
oftheir involvement in the metabolism ofphysiological chemicals
active in inter-and intracellular signalling, including steroid
hormones, eicosanoids and fatty acids (Capdevila et al, 1992).
The liver is the major normal tissue that expresses P450, while
specific forms of P450 are expressed in several different normal
extra-hepatic tissues, including small intestine, kidney and lung
(Schwartzman et al, 1990; Kaminsky and Fasco, 1992; Shimada et
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al, 1992; Murray and Burke, 1995). There is some evidence to
indicate that individual forms of P450 are expressed in tumours,
and previous studies have shown increased expression of indi-
vidual forms of P450 in different types of malignant tumour
(Foster et al, 1993; Murray et al, 1993; Kivisto et al, 1995b;
Nakajima et al, 1996), including tumours of the oesophagus
(Murray et al, 1994) and colon (McKay et al, 1993). In this study,
we have investigated the expression of P450 in stomach cancer
and compared it with normal stomach and different types of
intestinal metaplasia, the major precursor lesion of stomach
cancer.
MATERIALS AND METHODS
Tissue
Samples of tissue were obtained from gastrectomy specimens
submitted to the Department of Pathology, University of
Aberdeen. A total of 39 tumours were studied consisting of 24
tumours from men and 15 tumours from women (age range 38-84
years). Blocks of tumour and non-tumour tissue were fixed in
neutral-buffered formalin for 24 h and then embedded in wax.
Sections 5,m in thickness were cut and mounted on amino-
propyltriethoxy silane (Sigma, Poole, Dorset, UK)-coated slides
and used for immunohistochemistry and mucin histochemistry.
One section from each block was stained with haematoxylin and
eosin for histology. Histologically, all the tumours were primary
adenocarcinomas of stomach. The tumours were classified
according to Lauren (1965), and there were 12 (31%) tumours of
diffuse type and 27 (69%) tumours ofintestinal type. TNM staging
of tumours showed that there were five (13%) stage la tumours,
three (8%) stage lb tumours, 15 (39%) stage 2 tumours, 15 (39%)
stage 3 tumours and one (3%) stage 4 tumour.
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Table 1 The presence [number (percentage)] of individual P450s in
different histological types of gastric cancer
Histological type of tumour
Diffuse Intestinal Total
CYPlA
Positive 5 (13) 15 (38) 20 (51)
Negative 7 (18) 12 (31) 19 (49)
CYP2E1
Positive 0 0 0
Negative 12 (31) 27 (69) 39 (100)
CYP3A
Positive 2 (5) 9 (23) 11 (28)
Negative 10 (26) 18 (46) 28 (72)
Table 2 The presence [number (percentage)] of individual P450s in
different stages of gastric cancer
Tumour stage
la 1b 2 3a 4 Total
CYPlA
Positive 1 (3) 1 (3) 8 (20) 9 (22) 1 (3) 20 (51)
Negative 4 (10) 2 (5) 7 (19) 6 (15) 0 19 (49)
CYP2E1
Positive 0 0 0 0 0 0
Negative 5 (13) 3 (8) 15 (38) 15 (38) 1 (3) 39 (100)
CYP3A
Positive 2 (5) 0 4 (10) 5 (13) 0 11 (28)
Negative 3 (8) 3 (8) 11 (28) 10 (25) 1 (3) 28 (72)
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Figure 1 CYPlA immunoreactivity in diffuse type of gastric cancer (arrow
identifies representative positive tumour cells)
Mucin staining was performed with the high iron diamine alcian
blue method to aid the identification of the different types of
intestinal metaplasia (Filipe, 1990). Tissue sections were dewaxed,
rehydrated and washed in cold water and then incubated overnight
at room temperature with N-N'-dimethyl-m-phenylene diamine
dihydrochloride (Sigma) and N-N'-dimethyl-p-phenylene diamine
dihydrochloride (Sigma). The sections were then washed in water
and stained with 1% alcian blue (Filipe, 1990).
Figure 2 CYP3A immunoreactivity in poorly differentiated gastric cancer of
intestinal type (arrow identifies representative group of positive tumour cells)
Immunohistochemistry
CYPlA immunoreactivity was identified with a polyclonal anti-
body (Murray et al, 1993; Weaver et al, 1994) thatrecognizes both
CYPlAI and CYP1A2, while CYP2El was identified with a
rabbit polyclonal antibody obtained from Oxford Biomedical
Research (Oxford, MI, USA). CYP3A immunoreactivity was iden-
tified with a monoclonal antibody (HL3) thatrecognizes CYP3A4,
CYP3A5 and CYP3A7 (Murray et al, 1988). Sites ofimmunoreac-
tivity were identified using an alkaline phosphatase anti-alkaline
phosphatase (APAAP) technique (McKay et al, 1993). Sections of
stomach were dewaxed, rehydrated and washed in 0.05 M Tris-
HCI, pH 7.6, containing 150 mm sodium chloride (TBS). The
primary antibodies were each applied for 60 min at room tempera-
ture at the following dilutions: CYPIA 1:250, CYP2E1 1:500;
HL3 was applied as undiluted tissue culture supematant for
60 min. Mouse anti-rabbit immunoglobulin (1:100, Dako, High
Wycombe, Berks; omitted for monoclonal antibody), rabbit anti-
mouse immunoglobulin (1:100, Dako) and monoclonal APAAP
(1:100, Dako) were subsequently applied. Between application of
each antibody the sections were washed for three 5-min periods
in TBS. Sites of bound alkaline phosphatase were demonstrated
colorimetrically using a solutioncontaining 3 mg ofbromo-chloro-
indolyl phosphate (Sigma), 10 mg of nitro blue tetrazolium
(Sigma), 6 mg of sodium azide and 4 mg oflevamisole (Sigma) in
10 ml of 0.05 M Tris-HCl buffer, pH 9.0, containing 0.2% magne-
sium chloride. After incubating the sections for 30 min at room
temperature, the enzyme reaction was stopped by washing the
sections for 5 min in cold tap water. The slides were then air dried
and mounted in glycerinejelly. The sections were examined using
bright-field light microscopy to establish the presence or absence
ofimmunostaining and its distribution. TBS inplace oftheprimary
antibody was used as a negative control, while normal liver that
had been obtained from partial hepatectomy specimens and fixed
in formalin was used as a positive control.
RESULTS
CYP1A immunoreactivity was identified in 51% (20) of tumours,
whereas immunoreactivity for CYP3A was identified in 28% (11)
of tumours (Table 1). There was no CYP2E1 reactivity in any of
the tumours. CYPIA and CYP3A were identified in both histolog-
ical types of stomach cancer (Table 1), and there was no correla-
tion between the histological type or tumour stage (Table 2) and
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Figure 3 Immunoreactivity for CYP3A in normal stomach is confined to Figure 4 CYP3A immunoreactivity in type 1 intestinal metaplasia is present
mast cells (arrow identifies immunoreactive mast cell). There is no in columnar absorptive epithelial cells (arrow). Mast cells (arrow head) also
immunoreactivity in normal stomach mucosa show positive immunoreactivity
P450 expression. Both CYPlA and CYP3A immunoreactivity
were present within the cytoplasm of tumour cells, and there was
no apparent variation in the intensity ofimmunoreactivity in indi-
vidual tumours for either of these P450s (Figures 1 and 2). There
was no immunoreactivity for P450 in stromal cells or smooth
muscle cells.
There was no P450 immunoreactivity in normal gastric epithe-
lium, stromal cells or smooth muscle cells. However, CYP3A
immunoreactivity was identified in mast cells that were present
within the stomach wall (Figure 3).
In type 1 intestinal metaplasia, the columnar absorptive cell of
this type of metaplasia consistently showed CYP3A immunoreac-
tivity with stronger immunoreactivity of the columnar cells nearer
the surface (Figure 4). There was no immunoreactivity forCYP3A
in goblet cells. CYPlA showed immunoreactivity in 20% ofcases
and the distribution of immunoreactivity was identical to that
observed for CYP3A. In type 2 intestinal metaplasia, CYP3A
immunoreactivity was present in only 20% of cases, while there
was no significant immunoreactivity for CYP3A in type 3 meta-
plasia. CYPIA immunoreactivity was present in 5% ofboth type 2
and type 3 intestinal metaplasia. Both CYPIA and CYP3A
immunoreactivity were localized to absorptive epithelial cells,
while there was no immunoreactivity in mucin-secreting cells.
CYP2E1 immunoreactivity was not detected in any type of
intestinal metaplasia.
DISCUSSION
The increased expression of P450 in stomach cancer compared
with normal stomach provides further evidence for the concept
that specific forms ofP450 are significantly expressed in tumours.
The forms ofP450 investigated in this study represent some ofthe
major P450s that are involved in metabolizing xenobiotics. The
CYPIA subfamily consists of two closely related forms, with
CYPlAl being an inducible P450 primarily in extrahepatic tissues
while CYP1A2 is constitutively expressed in liver (Schweikl et al,
1993). However, CYPlAl and CYP1A2 have distinct substrate
specificities. CYP2E1 is an alcohol-inducible form ofP450 mainly
present in liver and is involved in the metabolism ofnitrosamines
(Koop, 1992). The CYP3A family consists of three forms:
CYP3A4, CYP3A5 and CYP3A7. CYP3A4 is the major form of
P450 present in normal liver, while CYP3A5, although less
frequently expressed in liver, is present in a variety ofextrahepatic
tissues, including small intestine (Kaminsky and Fasco, 1992).
CYP3A7 is the major form of P450 present in fetal liver (Scheutz
et al, 1994) and has a slightly different substrate specificity
compared with both CYP3A4 and CYP3A5 (Kitada and
Kamataki, 1994).
CYPlA has been shown previously to be expressed in other
malignant tumours, including tumours of the alimentary tract
(McKay et al, 1993; Murray et al, 1994). As CYPlAl is inducible in
extrahepatic tissues, it is probable that it is CYPlAl or a CYPlAl-
related protein rather than CYP1A2 that is present in tumours.
CYP3A was identified in approximately 30% ofgastric carcinomas,
and CYP3A has been identified in several types of malignant
tumours, including breast cancer (Murray et al, 1993), colon cancer
(McKay et al, 1993) and lung cancer (Kivisto et al, 1995b). As all
forms ofCYP3A are recognized by the antibody used in this study,
it is possible that CYP3A7 is present in tumourcells.
The presence of individual forms of P450 in stomach cancer
may provide molecular targets for anti-cancer drugs. One anti-
cancer agent that is ofparticular interest is AQ4N, an alkylamino-
anthroquinone, which is an inhibitor of both topoisomerase I and
topoisomerase II (Paterson, 1993). This compound is activated by
CYP3A and, in hypoxic conditions, as is likely to exist in tumours,
produces a cytotoxic metabolite of high potency, whereas in
normo-oxic conditions there is no cytotoxicity (Paterson, 1993).
This drug could be considered for use in CYP3A-containing
stomach cancers.
The current model for the development of gastric cancer
proposes that this tumour develops from normal stomach through
morphologically recognizable phases of intestinal metaplasia and
dysplasia (Correa, 1988). An important factor in the pathogenesis
of gastric cancer is the presence within the stomach ofpotentially
carcinogenic substances. Correa's model of gastric carcinogenesis
suggests that carcinogens can be produced locally in the stomach
as a consequence of Helicobacter pylori infection and/or can be
dietary in source. As environmental factors, particularly dietary
carcinogens and procarcinogens, have been strongly implicated in
the development of stomach cancers, it is important to determine
the expression of P450 in normal stomach and during gastric
carcinogenesis.
The different types ofintestinal metaplasia can be classified into
three types according to morphology and mucin staining (Filipe,
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1990; Stemmerman, 1994). Type 1 intestinal metaplasia is similar
morphologically and in certain phenotypic characteristics similar
to small intestinal epithelium, whereas type 2 and type 3 intestinal
metaplasia contain elements of both gastric and intestinal epithe-
lium, particularly large intestinal epithelium.
In this study, we have shown that there is no detectable P450 in
normal stomach, with the exception of CYP3A immunoreactivity
in mast cells as previously described (Murray et al, 1988).
However, CYP3A immunoreactivity was consistently identified in
type 1 intestinal metaplasia, and immunoreactivity was present in
absorptive cells. The most intense CYP3A immunostaining was
present in cells closest to the surface, thus mirroring the distribu-
tion and cellular localization seen in normal small intestinal
epithelium, which shows a gradient of CYP3A immunoreactivity
from crypt to villus tip (Murray et al, 1988; McKinnon et al, 1995),
with maximum immunoreactivity present in mature absorptive
cells at the tip ofthe villi. This finding suggests that the expression
of P450 in metaplastic intestinal epithelium is an intrinsic pheno-
typic property ofthose cells that is not influenced by the acid envi-
ronment of the stomach. The presence of CYP3A in type 1
intestinal metaplasia also suggests that CYP3A may have a role in
the early stages of gastric carcinogenesis, as CYP3A has been
shown to be capable of activating food-derived heterocyclic
amines to mutagenic products, and this reaction is enhanced in the
presence of flavonoids, which are a normal part of the diet
(McKinnon et al, 1992). CYP3A was not present in type 3
intestinal metaplasia, thus reflecting the expression ofthis P450 in
normal colonic epithelium where there is only a negligible amount
ofCYP3A (Massaad et al, 1992; McKay et al, 1993).
Epidemiological evidence has implicated dietary nitroso
compounds in the development of stomach cancer (Correa, 1988).
However, although CYP2E1 is the main form of P450, which in
vitro can metabolize nitrosamines (Koop, 1992), the absence of
this P450 from normal and metaplastic epithelium in stomach
would suggest that there is unlikely to be metabolism of these
compounds in normal stomach, while, in metaplastic stomach,
metabolism of nitrosamines could perhaps be carried out by other
forms of P450, possibly CYP3A. In oesophagus, a poorly charac-
terized form of P450 that is capable of metabolizing nitrosamines
(Huang et al, 1992) and is thought to be distinct to CYP2E1 has
been identified, and further investigation is required to determine
the precise identity of that form and to establish whether it is also
found in stomach.
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